Clinical Trials in China / NCT07180264
Recruiting
Observational
Trastuzumab Deruxtecan in Advanced Breast Cancer
NCT07180264 · tracked via the Priya Life Science China tracker
Condition(s) studied
Advanced Breast Cancer
Investigational drug(s) / intervention(s)
Trastuzumab deruxtecan: Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.
Study summary
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Eligibility
Inclusion Criteria:
* Aged ≥18 and older
* Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
* ECOG 0-1
Exclusion Criteria:
* During pregnancy and lactation
Primary outcome measure(s)
- Progression-Free Survival (PFS) — From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)
The time from the date of starting trastuzumab deruxtecan to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiaotong University | Shanghai | China | Recruiting |
On this site
📄 Enhertu (trastuzumab deruxtecan) drug profile →More Wenjin Yin trials in China
The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis
Active, not recruiting
The Association Between Blood Routine Parameters and Breast Cancer Prognosis
Active, not recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07180264 on ClinicalTrials.gov ↗ ← All trials in China